Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
2 competing products in clinical development for Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
Pipeline by Phase
Phase 11
Phase 21
All Products (2)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Tazemetostat | Eisai | Phase 2 | Completed | 35 |
| Tazemetostat | Eisai | Phase 1 | Completed | 29 |